Almost four decades ago,the characterization of the human immunodeficiency virus type 1(HIV-1)genome with the participation of the Haseltine laboratory at Harvard Medical School(Ratner et al.,1985)ushered in the antir...Almost four decades ago,the characterization of the human immunodeficiency virus type 1(HIV-1)genome with the participation of the Haseltine laboratory at Harvard Medical School(Ratner et al.,1985)ushered in the antiretroviral era and established the framework for the genomic-and later multiple omics-based development of targeted antiviral drugs.Battles with pandemic HIV-1 taught us that multitargeted combination antiviral therapy is needed to control pathogens that rapidly adapt to selective pressures from the immune system,vaccines,and therapeutic monoclonal antibodies.展开更多
文摘Almost four decades ago,the characterization of the human immunodeficiency virus type 1(HIV-1)genome with the participation of the Haseltine laboratory at Harvard Medical School(Ratner et al.,1985)ushered in the antiretroviral era and established the framework for the genomic-and later multiple omics-based development of targeted antiviral drugs.Battles with pandemic HIV-1 taught us that multitargeted combination antiviral therapy is needed to control pathogens that rapidly adapt to selective pressures from the immune system,vaccines,and therapeutic monoclonal antibodies.
